Viz RV/LV vs ClearRead CT

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Viz.ai
VS
by Riverain Technologies

AI Verdict

Viz RV/LV is specifically designed for rapid pulmonary embolism risk stratification by automating right and left ventricular diameter measurements from CTPA scans. ClearRead CT, conversely, focuses on enhancing pulmonary nodule detection and coronary artery calcification analysis in CT scans for lung cancer screening and cardiovascular risk assessment. While both leverage AI for CT analysis in cardiology and pulmonology, they address distinct clinical conditions and diagnostic objectives.

Choose Viz RV/LV if…

Choose Viz RV/LV if your primary need is rapid, AI-driven risk stratification for suspected pulmonary embolism. This tool excels at automating RV/LV ratio measurements from CTPA scans, facilitating quick clinical decisions and enhancing care team coordination for time-sensitive PE cases.

View Viz RV/LV →

Choose ClearRead CT if…

Choose ClearRead CT if your focus is on comprehensive pulmonary nodule detection, characterization, and tracking, alongside coronary artery calcification analysis. Its advanced vessel suppression and nodule management features are ideal for lung cancer screening programs and improving diagnostic accuracy in cardiothoracic imaging workflows.

View ClearRead CT →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Viz RV/LV ClearRead CT
Pricing Unknown Contact for pricing
Deployment Cloud-based On-premise (stand-alone server, virtual machine) and Cloud
FDA Status Cleared AI-estimated Cleared AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

ClearRead CT

ClearRead CT focuses on seamless integration into existing PACS workflows, reducing reading times by up to 36% and allowing concurrent reading without additional applications. [cite: JSON, 30] This deep integration directly enhances the radiologist's efficiency within their established environment, minimizing workflow disruption. Viz RV/LV, while offering mobile access and communication, introduces a separate platform for care coordination.

Clinical Value

Viz RV/LV

Viz RV/LV has demonstrated a significant clinical impact, showing a 74% reduction in in-hospital mortality risk for pulmonary embolism patients when combined with PERT activation. While ClearRead CT offers strong improvements in nodule detection accuracy and reading efficiency, the direct reduction in patient mortality represents a more profound clinical outcome. Both tools are FDA-cleared and supported by clinical studies. [cite: JSON, 2, 5, 11]

Pricing & Value

Tie

Neither Viz RV/LV nor ClearRead CT provides publicly available pricing information, making a direct comparison of their cost-effectiveness or overall value impossible. [cite: JSON] Both require potential customers to contact the vendor for pricing details, which limits transparency in this dimension.

Enterprise Readiness

ClearRead CT

ClearRead CT offers superior deployment flexibility with both on-premise and cloud options, catering to diverse IT infrastructure preferences and security policies within large enterprises. [cite: JSON, 15] Its emphasis on vendor-neutral PACS integration and enterprise-wide capability across all CT manufacturers further enhances its readiness for broad adoption in complex healthcare systems.

Innovation

ClearRead CT

ClearRead CT features patented Vessel Suppression technology, which is a unique and fundamental innovation in image processing that significantly improves nodule conspicuity by removing obscuring vascular structures. [cite: JSON, 10, 15, 25, 27, 30, 35, 36] This distinct technological approach directly addresses a long-standing challenge in radiological interpretation. Viz RV/LV's innovation lies more in automating measurements and care coordination.

Support & Docs

Viz RV/LV

Viz.ai explicitly highlights a 'dedicated customer success team' comprising clinical and workflow specialists, customer success managers, and clinical research scientists, indicating a comprehensive and proactive support structure. This structured team approach suggests a more tailored and hands-on experience for customers, beyond standard documentation and webinars offered by both.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Viz RV/LV ClearRead CT
Primary Function Automates right and left ventricular diameter measurements from CTPA scans, providing a crucial RV/LV ratio for rapid pulmonary embolism risk stratification and enhanced care coordination within the Viz PE Solution. Enhances pulmonary nodule detection and coronary artery calcification analysis in CT scans, improving diagnostic accuracy, reducing reading times, and streamlining radiology workflows through advanced AI and vessel suppression technology.
Company Viz.ai RIVERAIN TECHNOLOGIES
Key AI Focus Automated Right Ventricle (RV) to Left Ventricle (LV) ratio measurement for suspected pulmonary embolism detection. Pulmonary Nodule Detection (solid, part-solid, ground glass), Patented Vessel Suppression, Nodule Characterization and Measurement, Automated Nodule Tracking, Coronary Artery Calcification (CAC) Scoring.
Specialties Supported Emergency Medicine, Pulmonology, Radiology Cardiology, Pulmonology, Radiology
Categories Cardiology AI, Clinical Decision Support & Reference, Radiology & Imaging AI Cardiology AI, Oncology AI, Radiology & Imaging AI

Videos

Demos, reviews, and walkthroughs featuring Viz RV/LV and ClearRead CT.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Viz RV/LV is designed for rapid pulmonary embolism (PE) risk stratification by automating right and left ventricular diameter measurements from CTPA scans, providing a crucial RV/LV ratio. ClearRead CT, on the other hand, is an AI suite for cardiothoracic health that enhances pulmonary nodule detection and coronary artery calcification (CAC) analysis in CT scans.
Viz RV/LV specifically provides automated right ventricle (RV) to left ventricle (LV) ratio measurements from volumetric CTPA acquisitions. ClearRead CT offers pulmonary nodule detection (solid, part-solid, ground glass), characterization (volume, diameter, location, type, depth), automated nodule tracking, and coronary artery calcification (CAC) scoring on ungated, non-contrast CTs.
Viz RV/LV is a seamless component of the Viz PE Solution, providing AI-powered alerts and a HIPAA-compliant communication platform for care coordination. ClearRead CT emphasizes seamless PACS integration and vendor-neutral processing, with output provided in DICOM format for review in PACS.
ClearRead CT reports a reduction in reading time by up to 36% and an improved detection accuracy with a 29% reduction in missed actionable nodules. Viz RV/LV aims for rapid pulmonary embolism risk stratification and enhanced care coordination, with studies showing high agreement between algorithmic and manual RV/LV ratio calculations.
Viz RV/LV uses an AI algorithm to identify and measure heart ventricles from CTPA scans to determine the RV/LV ratio. ClearRead CT employs advanced AI and patented vessel suppression technology to enhance the visualization and detection of pulmonary nodules and to quantify coronary artery calcification.
Both Viz RV/LV and ClearRead CT are FDA-cleared. Viz RV/LV explicitly states it is HIPAA-compliant and has a BAA. ClearRead CT states it is likely HIPAA-compliant and has a BAA, and recommends contacting the vendor for details, though it operates with the VA and other healthcare institutions.

Backers

Who funded each tool's parent company.

AI Tool Finder
AI-powered search. Results may not be comprehensive.